Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

1.

Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.

Spiridigliozzi GA, Heller JH, Kishnani PS, Van der Ploeg AT, Ebbink BJ, Aarsen FK, van Gelder CM, Van den Hout JM.

Neurology. 2013 Mar 19;80(12):1173. doi: 10.1212/WNL.0b013e31828b8af0. No abstract available.

PMID:
23509050
2.

Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up.

Spiridigliozzi GA, Heller JH, Kishnani PS.

Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):22-9. doi: 10.1002/ajmg.c.31323. Epub 2012 Jan 17.

PMID:
22253038
3.

Early cognitive development in children with infantile Pompe disease.

Spiridigliozzi GA, Heller JH, Case LE, Jones HN, Kishnani PS.

Mol Genet Metab. 2012 Mar;105(3):428-32. doi: 10.1016/j.ymgme.2011.10.012. Epub 2011 Oct 28.

PMID:
22217428
4.

Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up.

Heller JH, Spiridigliozzi GA, Crissman BG, McKillop JA, Yamamoto H, Kishnani PS.

J Child Adolesc Psychopharmacol. 2010 Dec;20(6):517-20. doi: 10.1089/cap.2009.0099.

5.

Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17.

Kishnani PS, Heller JH, Spiridigliozzi GA, Lott I, Escobar L, Richardson S, Zhang R, McRae T.

Am J Med Genet A. 2010 Dec;152A(12):3028-35. doi: 10.1002/ajmg.a.33730.

PMID:
21108390
6.

Oropharyngeal dysphagia in infants and children with infantile Pompe disease.

Jones HN, Muller CW, Lin M, Banugaria SG, Case LE, Li JS, O'Grady G, Heller JH, Kishnani PS.

Dysphagia. 2010 Dec;25(4):277-83. doi: 10.1007/s00455-009-9252-x. Epub 2009 Sep 10.

PMID:
19763689
7.

The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.

Kishnani PS, Sommer BR, Handen BL, Seltzer B, Capone GT, Spiridigliozzi GA, Heller JH, Richardson S, McRae T.

Am J Med Genet A. 2009 Aug;149A(8):1641-54. doi: 10.1002/ajmg.a.32953.

PMID:
19606472
8.

Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series.

Spiridigliozzi GA, Heller JH, Crissman BG, Sullivan-Saarela JA, Eells R, Dawson D, Li J, Kishnani PS.

Am J Med Genet A. 2007 Jul 1;143A(13):1408-13.

PMID:
17542008
9.

Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.

Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan JA, Eells RL, Li JS, Doraiswamy PM, Krishnan KR, Kishnani PS.

J Child Adolesc Psychopharmacol. 2006 Dec;16(6):755-65.

10.

Clinical trials in children with Down syndrome: issues from a cognitive research perspective.

Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan-Saarela JA, Li JS, Kishnani PS.

Am J Med Genet C Semin Med Genet. 2006 Aug 15;142C(3):187-95. Review.

PMID:
16838317
11.

Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.

Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, Kishnani PS.

Am J Med Genet A. 2004 Oct 15;130A(3):325-6. No abstract available.

12.

Donepezil use in Down syndrome.

Kishnani PS, Sullivan JA, Spiridigliozzi GA, Heller JH, Crissman BG.

Arch Neurol. 2004 Apr;61(4):605-6. No abstract available.

PMID:
15096417
13.

Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.

Heller JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, Kishnani PS.

Am J Med Genet A. 2003 Jan 15;116A(2):111-6.

14.

Donepezil for Down's syndrome.

Kishnani PS, Spiridigliozzi GA, Heller JH, Sullivan JA, Doraiswamy PM, Krishnan KR.

Am J Psychiatry. 2001 Jan;158(1):143. No abstract available.

PMID:
11136652
15.
16.

Perception and production of approximant consonants by normal and articulation-delayed preschool children.

Broen PA, Strange W, Doyle SS, Heller JH.

J Speech Hear Res. 1983 Dec;26(4):601-8.

PMID:
6199587
17.

Blood on the shroud of turin.

Heller JH, Adler AD.

Appl Opt. 1980 Aug 15;19(16):2742-4. doi: 10.1364/AO.19.002742.

PMID:
20234501
18.

Disease, the host defense, and Q-10.

Heller JH.

Perspect Biol Med. 1973 Winter;16(2):181-7. No abstract available.

PMID:
4689357
19.

Human chromosome abnormalities as related to physical and mental dysfunction.

Heller JH.

J Hered. 1969 Sep-Oct;60(5):239-48. Review. No abstract available.

PMID:
4244249
20.

A NEW RETICULOENDOTHELIAL SYSTEM STIMULATING AGENT ('RESTIM') FROM SHARK LIVERS.

HELLER JH, PASTERNAK VZ, RANSOM JP, HELLER MS.

Nature. 1963 Aug 31;199:904-5. No abstract available.

PMID:
14079899
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk